Does the media refer more to VTRS or AMRX?

In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 5 mentions for Viatris. Viatris' average media sentiment score of 0.61 beat Amneal Pharmaceuticals' score of 0.49 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor JAZZ or AMRX?

In the previous week, Jazz Pharmaceuticals had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.49 beat Jazz Pharmaceuticals' score of 0.44 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NBIX or AMRX?

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 11 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.87 beat Amneal Pharmaceuticals' score of 0.49 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or CORT?

In the previous week, Corcept Therapeutics had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 28 mentions for Corcept Therapeutics and 11 mentions for Amneal Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.73 beat Amneal Pharmaceuticals' score of 0.49 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 9 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AMRX or ELAN?

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 11 articles in the media. Elanco Animal Health's average media sentiment score of 0.66 beat Amneal Pharmaceuticals' score of 0.49 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amneal Pharmaceuticals (AMRX) Competitors

$18.71 +0.43 (+2.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$19.03 +0.32 (+1.71%)

As of 09/18/2026 07:49 PM Eastern

Compare

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Amneal Pharmaceuticals stock or one of its competitors? Amneal Pharmaceuticals's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Viatris has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.36	N/A
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18

Viatris presently has a consensus price target of $18.71, suggesting a potential upside of 10.41%. Amneal Pharmaceuticals has a consensus price target of $20.14, suggesting a potential upside of 7.66%. Given Viatris' higher possible upside, equities analysts plainly believe Viatris is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 5 mentions for Viatris. Viatris' average media sentiment score of 0.61 beat Amneal Pharmaceuticals' score of 0.49 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amneal Pharmaceuticals beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Amneal Pharmaceuticals' net margin of 5.05%. Jazz Pharmaceuticals' return on equity of 33.97% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Jazz Pharmaceuticals presently has a consensus target price of $286.72, suggesting a potential upside of 19.10%. Amneal Pharmaceuticals has a consensus target price of $20.14, suggesting a potential upside of 7.66%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Jazz Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Jazz Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Amneal Pharmaceuticals has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.66	-$356.15M	$14.50	16.60
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18

In the previous week, Jazz Pharmaceuticals had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.49 beat Jazz Pharmaceuticals' score of 0.44 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Neurocrine Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.20	$478.60M	$6.82	21.44
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18

Neurocrine Biosciences has a net margin of 20.91% compared to Amneal Pharmaceuticals' net margin of 5.05%. Neurocrine Biosciences' return on equity of 22.43% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 11 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.87 beat Amneal Pharmaceuticals' score of 0.49 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurocrine Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurocrine Biosciences currently has a consensus price target of $201.09, suggesting a potential upside of 37.52%. Amneal Pharmaceuticals has a consensus price target of $20.14, suggesting a potential upside of 7.66%. Given Neurocrine Biosciences' higher probable upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

Neurocrine Biosciences beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Corcept Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18
Corcept Therapeutics	$830.81M	14.35	$99.65M	$0.42	262.60

Amneal Pharmaceuticals currently has a consensus price target of $20.14, indicating a potential upside of 7.66%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 25.28%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.52% compared to Amneal Pharmaceuticals' net margin of 5.05%. Corcept Therapeutics' return on equity of 8.26% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Corcept Therapeutics	6.52%	8.26%	6.45%

Amneal Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 28 mentions for Corcept Therapeutics and 11 mentions for Amneal Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.73 beat Amneal Pharmaceuticals' score of 0.49 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 11 articles in the media. Elanco Animal Health's average media sentiment score of 0.66 beat Amneal Pharmaceuticals' score of 0.49 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18
Elanco Animal Health	$4.72B	2.37	-$232M	-$0.41	N/A

Amneal Pharmaceuticals currently has a consensus price target of $20.14, suggesting a potential upside of 7.66%. Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 29.92%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Amneal Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Elanco Animal Health	-3.96%	8.13%	3.99%

Summary

Elanco Animal Health beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.84B	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	38.18	797.25	275.79	25.40
Price / Sales	1.98	950.97	695.58	114.47
Price / Cash	11.71	88.44	77.42	51.66
Price / Book	-81.35	10.53	10.46	6.33
Net Income	$72.06M	$2.82B	$3.49B	$358.33M
7 Day Performance	9.99%	1.69%	0.59%	1.12%
1 Month Performance	3.31%	0.83%	-2.01%	-2.67%
1 Year Performance	90.72%	3.90%	18.09%	6.01%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	3.3675 of 5 stars	$18.71 +2.4%	$20.14 +7.7%	+90.7%	$5.84B	$3.02B	38.18	8,500	Trending News Analyst Forecast High Trading Volume
VTRS Viatris	2.4208 of 5 stars	$16.60 -0.4%	$18.57 +11.9%	+71.9%	$19.07B	$14.74B	N/A	30,000	Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.3551 of 5 stars	$240.23 -2.3%	$286.72 +19.4%	+83.5%	$15.61B	$4.60B	16.59	2,890
NBIX Neurocrine Biosciences	4.7846 of 5 stars	$149.87 -4.7%	$201.09 +34.2%	+0.4%	$15.25B	$3.37B	21.99	2,000	Analyst Upgrade Insider Trade
CORT Corcept Therapeutics	4.1817 of 5 stars	$109.77 -1.8%	$138.17 +25.9%	+38.2%	$11.87B	$761.41M	261.52	730	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Which has more risk & volatility, VTRS or AMRX?

Do insiders & institutionals hold more shares of VTRS or AMRX?

Is VTRS or AMRX more profitable?

Which has better earnings and valuation, VTRS or AMRX?

Do analysts prefer VTRS or AMRX?

Does the media refer more to VTRS or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Do insiders and institutionals hold more shares of JAZZ or AMRX?

Is JAZZ or AMRX more profitable?

Do analysts prefer JAZZ or AMRX?

Which has more risk and volatility, JAZZ or AMRX?

Which has stronger earnings and valuation, JAZZ or AMRX?

Does the media favor JAZZ or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Which has preferable valuation & earnings, NBIX or AMRX?

Is NBIX or AMRX more profitable?

Does the media refer more to NBIX or AMRX?

Which has more risk and volatility, NBIX or AMRX?

Do institutionals & insiders hold more shares of NBIX or AMRX?

Do analysts rate NBIX or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Which has better valuation & earnings, AMRX or CORT?

Do analysts rate AMRX or CORT?

Do institutionals and insiders believe in AMRX or CORT?

Is AMRX or CORT more profitable?

Which has more risk & volatility, AMRX or CORT?

Does the media refer more to AMRX or CORT?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Does the media prefer AMRX or ELAN?

Do institutionals and insiders hold more shares of AMRX or ELAN?

Which has stronger earnings and valuation, AMRX or ELAN?

Do analysts rate AMRX or ELAN?

Which has more risk & volatility, AMRX or ELAN?

Is AMRX or ELAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools